Table 1.
Demographic and clinical information of patients, and treatments.
| Patients (n = 36) | |
|---|---|
| AT DIAGNOSIS | |
| Age, median years (range) | 54 (29–68) |
| Disease, n (%) | |
| Localized | 19 (52.8) |
| Locally advanced | 4 (11.1) |
| Metastatic | 13 (36.1) |
| Tumor size, n (%) * | |
| <50 mm | 5 (17.9) |
| ≥50 mm | 23 (82.1) |
| Histologic grade, n (%) * | |
| Low | 7 (28.0) |
| High | 18 (72.0) |
| Mitotic index, n (%) * | |
| 0–15/10 HPF | 11 (50.0) |
| >15/10 HPF | 11 (50.0) |
| PREVIOUS TREATMENTS | |
| Adjuvant therapy, n (%) | 21 (58.4) |
| Radiotherapy | 10 (27.8) |
| Chemotherapy | 5 (13.9) |
| Both | 6 (16.7) |
| Chemotherapy prior to trabectedin (any line for relapsed disease), n (%) | 30 (83.3) |
| Number of lines, median (range) | 2 (0–3) |
| Anthracycline therapy immediately before trabectedin, n (%) | 5 (16.7) |
| TRABECTEDIN TREATMENT | |
| Age at onset of trabectedin treatment, median years (range) | 57 (36–70) |
| ECOG performance status at starting treatment, n (%) * | |
| 0–1 | 28 (87.5) |
| 2–3 | 4 (12.5) |
| Number of trabectedin cycles, median (range) | 6 (3–25) |
| Reasons for trabectedin discontinuation, n (%) | |
| Tumor progression | 30 (83.3) |
| Intolerance | 3 (8.3) |
| Complete tumor response | 1 (2.8) |
| Patient’s decision | 1 (2.8) |
| Physician’s decision | 1 (2.8) |
ECOG, Eastern Cooperative Oncology Group; HPF, high-power fields
*
Data not available for some patients.